6 news items
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
IVVD
15 Apr 24
and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent
Invivyd Announces CEO Transition
IVVD
12 Apr 24
-to-day leadership of the company with Jeremy, who is primarily responsible for our commercial execution, and I personally look forward to partnering
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
IVVD
4 Apr 24
medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19
Invivyd Announces FDA Authorization For Emergency Use Of PEMGARDA For Pre-Exposure Prophylaxis Of COVID-19
IVVD
22 Mar 24
and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent
7l7 6o8m4szvj695slsixb6kp
IVVD
22 Mar 24
an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure
- Prev
- 1
- Next